Ann: Shareholder Briefing, page-96

Hi guys

Went along to the Melbourne Q & A tonight - only four people turned up including myself but it was an interesting session . Kathryn Harrison presented and also introduced Hugh Alsop . Both were upbeat and as Ahmed has suggested in his post , out-licensing/partnering with a cashed up entity would be a considered option IF phase 2a results are good and entice interest . If not then DXB would continue on with phase 2 evaluations into late 2018. Definitely they are hoping for interest from bigger players once phase 2a results are released , hence Hugh Alsop's recent appointment as this is one of his areas of expertise .

Investor wise , while the DMX-200 clinical trial is definitely a stimulus to become involved in Dimerix I would suggest as Ahmed and Prestonian have eluded to , it is the technology they have developed with their HIT platform that underpins their growth/sustainability. They are the only company that has the technology to identify GPCR's (G-Protein Coupled Receptors) which work together - known as heterodimers . So instead of the current approach of looking at single receptor sites (monomers) as a target for drug therapies they have the technology to identify two different GPCR's that work together in synergy , which if you think about it is quite ground breaking and exciting. Kathryn spoke about this and indicated it is opening up multiple opportunities for new therapeutic development and there were 5 or so companies ( she could not name) who were showing interest in utilizing this technology. Refer to Prestonian's post above re NASH , MS , Cancer Fatigue etc .

So while we wait for the outcome of phase 2a for DMX-200 and look at DXB 's possible re rating as happened to companies such as ChemoCentrix , Retrophin and Questcor involved in CKD research, the bigger picture long term may be Dimerix's Receptor HIT pipeline and drug therapy development. While we talk about Retrophin , ChemoCentrix etc it is interesting to note the market values of companies currently involved in drug discovery platforms .

Examples of these are ;

Heptares Therapeutics : . Phase 1b plus multiple pre-clinical leads
. GPCR discovery platform
. Aquired by Sosei Feb 2015 for US$400 million

Trevena : .GPCR discovery platform
. NASDAQ Listed : TRVN
. Market Cap : US$75 million

Receptos : . Phase3 and Phase2 assets
. GPCR discovery platform
. Acquired by Celgene July 015 for US6 billion.

Dimerix's GPCR discovery platform HIT (Heterodimers) technology is unique and none of the above companies hold this . Exciting times ahead .

As always good luck to all with your holdings .

Kind Regards . Wardy34